Rybelsus(Semaglutide)
NVO
Medicare prescription drug cost, prescriptions and prescribers, 2024 · made by Novo Nordisk A/S
$1.89B
Medicare cost, 2024
$1.89B
Medicare cost, 2024
Medicare drug plans spent $1.9 billion on Rybelsus (semaglutide) in 2024, for 1.3 million prescriptions and refills filled by 309,850 patients. It ranks 27th among all drugs by Medicare drug plan spending. California accounts for the most spending ($229.4 million, 12% of the total). It is made by Novo Nordisk A/S (NVO).
Medicare cost, 2024
$1.89B
+13.4% from 2023
Prescriptions
1.3M
$1,509.98 per claim
Patients
310K
125,776 prescribers
Total spending, 2024
$1.89B
$6,097.18 per patient
Questions and answers
How much does Medicare spend on Rybelsus?
Medicare prescription drug plans paid $1.89B for Rybelsus in 2024, for 1,251,182 prescriptions and refills to 309,850 patients (up 13.4% from 2023). The average cost per claim was $1,509.98.
Which state spends the most on Rybelsus?
California had the highest Medicare cost for Rybelsus in 2024: $229.4M for 157,307 claims, followed by New York ($171.6M).
Who prescribes Rybelsus the most?
Wei Y Sun, nephrology in New York, NY, had the highest Medicare cost for Rybelsus in 2024: 853 claims costing $872K.
Who makes Rybelsus?
Rybelsus is made by Novo Nordisk A/S (NVO), listed in the Medicare spending data as Novo Nordisk.
Spending over the years
Medicare spending by year
All plans and makers
Prescriber data: cost by year
Medicare spending on Rybelsus was $1.89B in 2024, the highest year shown.
By state
Where the prescribers practice, 2024
Medicare cost by state
States with the highest cost
Top prescribers of Rybelsus, 2024
By Medicare drug cost
| Prescriber | Type | Claims | Patients | Cost |
|---|---|---|---|---|
| Wei Y Sun New York, NY | Nephrology | 853 | 127 | $872K |
| Yun Feng New York, NY | Endocrinology | 719 | 142 | $856K |
| Duc H Phan Houston, TX | Internal Medicine | 521 | 123 | $812K |
| George C Liu New York, NY | Internal Medicine | 401 | 94 | $768K |
| Phong H Bui Fountain Valley, CA | Internal Medicine | 431 | 87 | $633K |
| Ivana Sheu San Francisco, CA | Endocrinology | 429 | 84 | $613K |
| Sharon H Kim Bronx, NY | Endocrinology | 364 | 76 | $592K |
| Eliscer Guzman New York, NY | Internal Medicine | 377 | 97 | $563K |
| Bao Q Nguyen Stockton, CA | Family Practice | 581 | 69 | $561K |
| Zihe Shan Brooklyn, NY | Internal Medicine | 297 | 70 | $541K |
| Michael W Lin San Gabriel, CA | Endocrinology | 402 | 79 | $535K |
| Sheikh M Masood Madera, CA | Nephrology | 525 | 109 | $518K |
| Isaiah Pittman IV Terre Haute, IN | Endocrinology | 374 | 112 | $489K |
| Rodolfo Guzman Bronx, NY | Endocrinology | 296 | 67 | $480K |
| Bashar G Saad San Dimas, CA | Endocrinology | 323 | 101 | $475K |
| Tu N Truong San Diego, CA | Internal Medicine | 267 | 68 | $473K |
| Jerry L Jurado Union City, NJ | Family Practice | 212 | 65 | $472K |
| Manavendra Bakhshi Philadelphia, PA | Cardiology | 407 | 68 | $470K |
| Kathrine A Gold Brooklyn, NY | Internal Medicine | 269 | 66 | $469K |
| Enrique J Griego McAllen, TX | Family Practice | 281 | 94 | $463K |
| Dinorah J Nutis El Paso, TX | Internal Medicine | 204 | 64 | $428K |
| Ashvin Vijayakumar Philadelphia, PA | Hospitalist | 378 | 51 | $405K |
| Shailesh Baral York, PA | Endocrinology | 265 | 71 | $404K |
| Fufu He Brooklyn, NY | Family Practice | 266 | 45 | $399K |
| Bosheng Qiu Alhambra, CA | Internal Medicine | 379 | 61 | $385K |
Prescriber data by year
| Year | Prescribers | Claims | Patients | Cost |
|---|---|---|---|---|
| 2022 | 81,128 | 686,142 | 184,563 | $974.6M |
| 2023 | 114,075 | 1,074,653 | 285,571 | $1.67B |
| 2024 | 125,776 | 1,251,182 | 309,850 | $1.89B |
Makers, 2024
Spending by manufacturer as listed in the spending data
| Manufacturer | Claims | Spending |
|---|---|---|
| Novo Nordisk | 1,251,733 | $1.89B |
More drugs: Medicare drug spending and the Prescriptions view.
Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.
Through September 2026, 78,023 side-effect reports named semaglutide, the active ingredient of Rybelsus (reports from 2013 on). 39,105 of them (50.1%) were serious, 1,364 named a death and 15,565 named a hospital stay. The reactions named most often were nausea, off label use and vomiting. 67,168 reports came in the last 5 years (since 2022).
How to read these numbers
- A report shows that a patient, doctor or drug company suspected a link. It does not prove that the drug caused the effect.
- Counts are not risk rates. They depend on how many people use the drug, how long it has been sold, news and reporting habits, so they do not show which drug is safer.
- The newest months are partial: reports keep arriving late.
Reports, all years
78,023
20,019 in 2025 (+39.9% from 2024)
Serious
50.1%
39,105 reports
Deaths named
1,364
1.7% of reports
Hospital stays
15,565
19.9% of reports
Reports by year
Serious reports include those that name a death, a hospital stay, a disability or another serious outcome.
Reports received by year
2026 is the year so far.
Reports naming a death or a hospital stay
One report can name both
Reactions
Reactions named most often
All years. Share = part of all reports in that period. A report can name several reactions.
Patients
As given in the reports; many reports leave sex or age out.
Sex of the patient
All years
Age of the patient
Age when the effect started, all years
Questions and answers
How many side-effect reports name Rybelsus?
78,023 reports from 2013 through September 2026 named semaglutide, the active ingredient of Rybelsus. 39,105 of them (50.1%) were serious, 1,364 named a death and 15,565 named a hospital stay.
What are the most reported side effects of Rybelsus?
11,150 reports named nausea, the reaction named most often, followed by off label use (7,890) and vomiting (7,332). In the last 5 years the reaction named most often was nausea (9,222 reports). A report can name several reactions.
How many side-effect reports named Rybelsus in 2025?
20,019 reports were received in 2025 (+39.9% from 2024). 2026 so far: 17,010 reports through September 2026, and more keep arriving late.
Do side-effect reports prove that Rybelsus caused a problem?
No. A report shows that a patient, doctor or drug company suspected a link; it does not prove that Rybelsus caused the effect. Report counts depend on how widely a drug is used, how long it has been sold, news and reporting habits, so they are not risk rates and do not show which drug is safer.
Related pages
- Other Medicare drug pages with semaglutide: Ozempic, Wegovy
- Makers on the stock market:
NVO·NVO drug pipeline - Drug approvals (3 approvals on file for semaglutide) · Clinical trials · Medicare drug spending
Side-effect reports from official public data, counted per active ingredient (semaglutide) by the year the report was received, so the brand and generic pages of one ingredient show the same reports. A report can name several drugs and several reactions and counts for each. Reaction names are the standard medical terms used in the reports. Reports whose product could not be matched to a drug are not counted. Updated November 2026.